Abstract
Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Mini-Reviews in Medicinal Chemistry
Title:Direct Inhibitors of Ras-Effector Protein Interactions
Volume: 16 Issue: 5
Author(s): Punit Upadhyaya, Walaa Bedewy and Dehua Pei
Affiliation:
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Abstract: Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Export Options
About this article
Cite this article as:
Upadhyaya Punit, Bedewy Walaa and Pei Dehua, Direct Inhibitors of Ras-Effector Protein Interactions, Mini-Reviews in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1389557515666151001141713
DOI https://dx.doi.org/10.2174/1389557515666151001141713 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Cancer Stem Cells in Hematological Disorders: Current and Possible New Therapeutic Approaches
Current Pharmaceutical Biotechnology Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Editorial [Hot topic: Contemporary Approaches in Cancer Therapy (Guest Editor: Riyaz Basha)]
Medicinal Chemistry Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4
Current Drug Metabolism Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Structural and Functional Organization of miRNAs
Current Pharmacogenomics Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations
Current Pharmacogenomics Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Furanocoumarin A: A Novel Anticancer Agent on Human Lung Cancer A549 Cells from Fructus liquidambaris
Anti-Cancer Agents in Medicinal Chemistry